Are you over 18 and want to see adult content?
More Annotations
A complete backup of vaultofvhs.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of artofjiujitsu.com
Are you over 18 and want to see adult content?
A complete backup of seumicroseguro.com
Are you over 18 and want to see adult content?
A complete backup of criaideias.com.br
Are you over 18 and want to see adult content?
A complete backup of bainbridgewa.gov
Are you over 18 and want to see adult content?
A complete backup of axuretechnologies.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of vacationrentalrehoboth.com
Are you over 18 and want to see adult content?
A complete backup of textilescoated.com
Are you over 18 and want to see adult content?
A complete backup of brandyfromthebottle.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of fid-gesundheitswissen.de
Are you over 18 and want to see adult content?
A complete backup of cybertigeranime.com
Are you over 18 and want to see adult content?
A complete backup of kesherisrael.org
Are you over 18 and want to see adult content?
A complete backup of fernandinabeachrealty.com
Are you over 18 and want to see adult content?
A complete backup of cristianmateica.com
Are you over 18 and want to see adult content?
Text
field.
GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—MHRA BACKS JEMPERLI, FIRST ANTI-PD-1 MONOTHERAPY FOR The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for UK pharma major GlaxoSmithKline’s Jemperli (dostarlimab), a programmed death receptor-1 (PD-1)-blocking antibody. The approval is BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
EISAI LAUNCHES REMITORO FOR PTCL AND CTCL IN JAPAN To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing MERGERS & ACQUISITIONS Agios to sell oncology business for up to $2 billion plus royalties. 22-12-2020. Shares of the Cambridge, Mass, U SA-based Agios Pharmaceuticals closed up more than 28% at $42.62 yesterday,. Agios Pharmaceuticals Biotechnology Companies, mergers and acquisitions France Management Oncology Servier Tibsovo vorasidenib.FKD THERAPIES OY
FKD Therapies Oy is a gene-based medicine developer, founded in 2011 and based in Kuopio, Finland. JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. OVER-THE-COUNTER NASAL SPRAY COULD BLOCK COVID-19 Over-the-counter nasal spray could block COVID-19. Austrian respiratory and ophthalmology specialist Marinomed Biotech has submitted for approval for its. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary fromthe
NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016. AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—MHRA BACKS JEMPERLI, FIRST ANTI-PD-1 MONOTHERAPY FOR The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for UK pharma major GlaxoSmithKline’s Jemperli (dostarlimab), a programmed death receptor-1 (PD-1)-blocking antibody. The approval is BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
EISAI LAUNCHES REMITORO FOR PTCL AND CTCL IN JAPAN To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing MERGERS & ACQUISITIONS Agios to sell oncology business for up to $2 billion plus royalties. 22-12-2020. Shares of the Cambridge, Mass, U SA-based Agios Pharmaceuticals closed up more than 28% at $42.62 yesterday,. Agios Pharmaceuticals Biotechnology Companies, mergers and acquisitions France Management Oncology Servier Tibsovo vorasidenib.FKD THERAPIES OY
FKD Therapies Oy is a gene-based medicine developer, founded in 2011 and based in Kuopio, Finland. JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. OVER-THE-COUNTER NASAL SPRAY COULD BLOCK COVID-19 Over-the-counter nasal spray could block COVID-19. Austrian respiratory and ophthalmology specialist Marinomed Biotech has submitted for approval for its. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary fromthe
NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016.NEWS - MCUREX
1 day ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
NEWS - HEARTSEED
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - ENZENE
1 day ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.NEWS - NOVOGENE
1 day ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.BIOTECHNOLOGY
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
ONCOLOGY - REGULATION, GENERICS, IMMUNO-ONCOLOGY The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
THE FDA TURNS TO AI TO ACCELERATE DRUG DEVELOPMENT AND 14-05-2020. Article FDA approvals dropped 16% in 2019, says GlobalData. 12-05-2020. Article Exscientia and Sumitomo Dainippon bring first AI-generated drug into human trials. 30-01-2020. Article UK invests to be 'world leader in saving lives through AI and genomics'. 08-08-2019.PHARMACEUTICAL
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
OVER-THE-COUNTER NASAL SPRAY COULD BLOCK COVID-19 Over-the-counter nasal spray could block COVID-19. Austrian respiratory and ophthalmology specialist Marinomed Biotech has submitted for approval for its. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary fromthe
AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - KHK4083
Kyowa Kirin to get $400 million upfront in KHK4083 licensing deal. 02-06-2021. Shares of Japanese drugmaker Kyowa Kirin (TYO: 4151) were up 8% at 3,560 yen on news of a lucrative licensing MORPHOSYS HOCKS ROYALTIES TO BUY CONSTELLATION PHARMA Royalty Pharma. MorphoSys. Shares of US cancer drug maker Constellation Pharmaceuticals closed up a massive 66.7% at $33.74 yesterday. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the POSITIVE PIVOTAL PHASE III DATA FOR ROCHE’S TECENTRIQ To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcingBIOSIMILARS NEWS
15-05-2021. Recently-formed Viatris, the combination of Mylan with Pfizer’s Upjohn business, has reported results. Article. Progress on proposed biosimilars of eye drugs Eylea and Lucentis. 04-05-2021. Article. Boehringer says data supports interchangeability of Cyltezo with Humira. 24-04-2021. Article. BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
NEWS - CAPSIGEN
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications.KINEDAK LAUNCH
Kinedak launch. 31-05-1992. Comments (0) Print. - Kinedak (epalrestat) has recently been launched in Japan by Ono Pharmaceutical. Ono expects the drug. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from thesharpest
AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - KHK4083
Kyowa Kirin to get $400 million upfront in KHK4083 licensing deal. 02-06-2021. Shares of Japanese drugmaker Kyowa Kirin (TYO: 4151) were up 8% at 3,560 yen on news of a lucrative licensing MORPHOSYS HOCKS ROYALTIES TO BUY CONSTELLATION PHARMA Royalty Pharma. MorphoSys. Shares of US cancer drug maker Constellation Pharmaceuticals closed up a massive 66.7% at $33.74 yesterday. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the POSITIVE PIVOTAL PHASE III DATA FOR ROCHE’S TECENTRIQ To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcingBIOSIMILARS NEWS
15-05-2021. Recently-formed Viatris, the combination of Mylan with Pfizer’s Upjohn business, has reported results. Article. Progress on proposed biosimilars of eye drugs Eylea and Lucentis. 04-05-2021. Article. Boehringer says data supports interchangeability of Cyltezo with Humira. 24-04-2021. Article. BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
NEWS - CAPSIGEN
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications.KINEDAK LAUNCH
Kinedak launch. 31-05-1992. Comments (0) Print. - Kinedak (epalrestat) has recently been launched in Japan by Ono Pharmaceutical. Ono expects the drug. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from thesharpest
LOGIN - THE PHARMA LETTER The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
BRIEF—FULL ANAKINRA COVID-19 PNEUMONIA RESULTS SET UP BRIEF—Full anakinra COVID-19 pneumonia results set up regulator talks. Full results have been presented from the investigator-sponsored SAVE-MORE study of anakinra in COVID-19 pneumonia by Swedish Orphan Biovitrum, the company more commonly-known as Sobi, and the Hellenic Institute for the Study of Sepsis. Day 28 results show early treatment BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
NEWS - BYONDIS
20 hours ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—METYRAPONE EFFECTIVE AND SAFE IN ENDOGENOUS CUSHING HRA Pharma Rare Diseases, an affiliate of privately-held French healthcare company HRA Pharma, has revealed data from the six-month extension of PROMPT, the first ever prospective study designed to evaluate metyrapone long-term efficacy and tolerability in NEWS - MOLNUPIRAVIR - THE PHARMA LETTER The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - WEGOVY
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - BIONTECH, VACCINES, GLOBAL - THEPHARMALETTER.COM The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
PHARMACEUTICAL
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
EISAI LAUNCHES REMITORO FOR PTCL AND CTCL IN JAPAN To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing MORPHOSYS HOCKS ROYALTIES TO BUY CONSTELLATION PHARMA Shares of US cancer drug maker Constellation Pharmaceuticals closed up a massive 66.7% at $33.74 yesterday Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
BRIEF—HU HUI BAO DEBUTS IN SHANGHAI BRIEF—Hu Hui Bao debuts in Shanghai. The major Chinese city Shanghai has launched its local version of Hui Min Bao, a government-backed, commercial insurance company underwritten healthcare insurance product that is complement to China's current national social healthcarescheme.
MERGERS & ACQUISITIONS Agios to sell oncology business for up to $2 billion plus royalties. 22-12-2020. Shares of the Cambridge, Mass, U SA-based Agios Pharmaceuticals closed up more than 28% at $42.62 yesterday,. Agios Pharmaceuticals Biotechnology Companies, mergers and acquisitions France Management Oncology Servier Tibsovo vorasidenib. JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. OVER-THE-COUNTER NASAL SPRAY COULD BLOCK COVID-19 Over-the-counter nasal spray could block COVID-19. Austrian respiratory and ophthalmology specialist Marinomed Biotech has submitted for approval for its. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary fromthe
NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016. AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
EISAI LAUNCHES REMITORO FOR PTCL AND CTCL IN JAPAN To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing MORPHOSYS HOCKS ROYALTIES TO BUY CONSTELLATION PHARMA Shares of US cancer drug maker Constellation Pharmaceuticals closed up a massive 66.7% at $33.74 yesterday Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
BRIEF—HU HUI BAO DEBUTS IN SHANGHAI BRIEF—Hu Hui Bao debuts in Shanghai. The major Chinese city Shanghai has launched its local version of Hui Min Bao, a government-backed, commercial insurance company underwritten healthcare insurance product that is complement to China's current national social healthcarescheme.
MERGERS & ACQUISITIONS Agios to sell oncology business for up to $2 billion plus royalties. 22-12-2020. Shares of the Cambridge, Mass, U SA-based Agios Pharmaceuticals closed up more than 28% at $42.62 yesterday,. Agios Pharmaceuticals Biotechnology Companies, mergers and acquisitions France Management Oncology Servier Tibsovo vorasidenib. JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. OVER-THE-COUNTER NASAL SPRAY COULD BLOCK COVID-19 Over-the-counter nasal spray could block COVID-19. Austrian respiratory and ophthalmology specialist Marinomed Biotech has submitted for approval for its. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary fromthe
NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016.GOVERNMENT AFFAIRS
BRIEF—India’s SII to extend freeze on exports of COVID-19 jabs. 19-05-2021. The world’s biggest vaccine maker, the Serum Institute of India (SII), plans to extend its halt on. Coronavirus Focus On Government Affairs India Infectious diseases Pharmaceutical Production Serum Institute of India Vaccines. InBrief.NEWS - ATC
1 day ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.NEWS - BYONDIS
2 hours ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BIOSIMILARS NEWS
15-05-2021. Recently-formed Viatris, the combination of Mylan with Pfizer’s Upjohn business, has reported results. Article. Progress on proposed biosimilars of eye drugs Eylea and Lucentis. 04-05-2021. Article. Boehringer says data supports interchangeability of Cyltezo with Humira. 24-04-2021. Article.NEWS - INDIVIOR
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - KHK4083
Kyowa Kirin to get $400 million upfront in KHK4083 licensing deal. 02-06-2021. Shares of Japanese drugmaker Kyowa Kirin (TYO: 4151) were up 8% at 3,560 yen on news of a lucrative licensing NEWS - BIONTECH, VACCINES, GLOBAL - THEPHARMALETTER.COM The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - ZEJULA
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
OVER-THE-COUNTER NASAL SPRAY COULD BLOCK COVID-19 Over-the-counter nasal spray could block COVID-19. Austrian respiratory and ophthalmology specialist Marinomed Biotech has submitted for approval for its. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary fromthe
This website uses cookies to improve your experience. Continue if youare OK with this.
Please read our privacy policyfor more
details.
_close_
* Login
* Subscribe
Search
Search
* Home
* M&A
* News
* News
* Pharmaceutical News * Biotechnology News* Generics News
* Biosimilars news
* Mergers & Acquisitions* Regulation
* World News
* In the Boardroom
TOP NEWS STORIES
* Bayer appoints new business development head for pharmaceuticalsPharmaceutical
* Free-spending Vertex bets $950 million to ‘transform the treatment paradigm for type 1 diabetes’Biotechnology
* In Depth
* In Depth
* Analysis
* Special Report
* Interview
* Expert View
* From our correspondent TOP IN DEPTH STORIES * Russian plans to establish production of orphan drugsPharmaceutical
* Global drugmakers look set for better protection of their legalrights in Russia
Generics
* In Brief
* Conferences
* Conferences
* AAIC 2019
* ASCO 2019
* ADA 2019
* ISPE 2019
* AACR Annual Meeting 2019* ATS 2019
* EULAR 2019
* WCD
* ESC Congress 2019
TOP CONFERENCES STORIES * Shares soar as The Medicines Company considers inclisiran’ ‘unprecedented potential’Biotechnology
* Positive data for Farxiga at ESC Congress in ParisBiotechnology
* Focus On
* Focus On
* Brexit
* FDA
* Pricing, reimbursement and access* EMA
* Russian market
* Trump administration* Asia Pacific
* Legal
* One to Watch Companies* Digital
* CEO Interviews
* Government Affairs TOP FOCUS ON STORIES * UK doctors’ union warns of ‘devastating’ impact of no dealon NHS
Pharmaceutical
* Ability to 'bridge the gap' key to making UK a biopharma powerhouseBiotechnology
* Events
* Companies
* Reports
* Therapy Areas
* Therapy Areas
* Dermatologicals
* Oncology
* Neurological
* Rare diseases
* Hematology
TOP THERAPY AREAS STORIES * More fixed-dose combo drugs are facing the axe in IndiaGenerics
* FDA and EMA convergence shows shared commitment to raisingstandards
Pharmaceutical
* Login
* Subscribe
THE PHARMA LETTER
Article
MIXED RESULTS FOR NOVARTIS’ ENTRESTO PRESENTED AT ESC02-09-2019
*
RARE DISEASES:
Article
ILLUMINATING DUCHENNE MUSCULAR DYSTROPHY*
FROM OUR CORRESPONDENT:Article
MORE FIXED-DOSE COMBO DRUGS ARE FACING THE AXE IN INDIA*
INTERVIEW:
Article
MUNDIPHARMA A COMPANY THAT IS TRANSFORMED, UNIQUE AND PARTNERSHIP-DRIVEN, SAYS MARCO CERATO*
EXPERT VIEW:
Article
CHALLENGES IN EXPANDING ACCESS TO ADVANCED HEALTHCARE TECHNOLOGIESArticle
ANALYSIS
ABILITY TO 'BRIDGE THE GAP' KEY TO MAKING UK A BIOPHARMA POWERHOUSE The UK’s departure from the European Union looks likely to dent many sectors at least in the short to medium term, but the biopharmaceutical industry is one that might just continue to shine, however damaging the exit from the trade bloc proves to be.LATEST IN BRIEF
* InBriefBRIEF—Endo debuts authorized generic of Noxafil in USA03-09-2019
* InBriefBRIEF—Guidelines recommend first-line use of SGLT2 inhibitors in type 2 diabetes with CV disease03-09-2019
* InBriefBRIEF—Sumitomo extends schizophrenia franchise in Asia03-09-2019
* InBriefBRIEF—Another delay in Roche takeover of Spark Therapeutic03-09-2019
LATEST PHARMACEUTICAL NEWS">
Article
BAYER APPOINTS NEW BUSINESS DEVELOPMENT HEAD FOR PHARMACEUTICALS03-09-2019
German pharma major Bayer has appointed Marianne De Backer as head of business development for pharmaceuticals. * ArticlePharma industry urges UK to spend more R&D infrastructure03-09-2019
* ArticleGrünenthal and UniQuest partner on novel chronic neuropathic pain drugs03-09-2019
* ArticleHelsinn out-licenses pracinostat in South America02-09-2019
* ArticleAugust 2019 pharmaceutical M&A round-up02-09-2019
LATEST BIOTECHNOLOGY NEWS">
Article
FREE-SPENDING VERTEX BETS $950 MILLION TO ‘TRANSFORM THE TREATMENT PARADIGM FOR TYPE 1 DIABETES’03-09-2019
US drugmaker Vertex Pharmaceuticals has taken another gamble outside its traditional cystic fibrosis… * ArticleMacrophage Pharma names Søren Bregenholt as CEO03-09-2019
* ArticleCidara Therapeutics rockets as it cashes in on rezafungin03-09-2019
* ArticleVelabs and alytas announce obesity deal03-09-2019
* ArticleZydus breaks ground with novel rabies biologic03-09-2019
LATEST GENERICS NEWS">
Article
GLOBAL DRUGMAKERS LOOK SET FOR BETTER PROTECTION OF THEIR LEGAL RIGHTSIN RUSSIA
02-09-2019
The disputes between manufacturers of original drugs and their Russian rivals may have a new twist in… * ArticleTentative approval of Alimta generic sends Mylan upwards30-08-2019
* ArticleChina relaxes import regs to improve access to affordabledrugs
30-08-2019
* ArticleMore fixed-dose combo drugs are facing the axe in India30-08-2019
* ArticleLupin divests Kyowa Criticare to Neopharma group22-08-2019
LATEST BIOSIMILARS NEWS">
Article
SANDOZ ACQUIRES RIGHTS TO TYSABRI BIOSIMILAR FROM POLISH FIRM03-09-2019
Swiss pharma giant Novartis’ Sandoz biosimilars division today announced that it has entered into a… * ArticleBiosimilar Humira contributes to massive NHS cost savings02-09-2019
* ArticleRichter launches its biosimilar teriparatide across Europe20-08-2019
* ArticleAmgen shares jump as it wins Enbrel biosimilar patent case10-08-2019
* ArticleMylan and Biocon launch biosimilar, Ogivri, in Australia02-08-2019
* Editor's Picks
* Most read
TOP 5 STORIES
1 of 5
*
AMGEN TO ACQUIRE OTEZLA IN MULTI-BILLION DOLLAR DEAL*
INDIAN HIGH COURT REVOKES NOVARTIS LUNG CANCER DRUG PATENT*
PERFORMANCE OF TOP-20 PHARMA COMPANIES IN 2018*
ILLUMINATING DUCHENNE MUSCULAR DYSTROPHY*
NOVARTIS JUMPS ON OFATUMUMAB MS DATATOP 5 STORIES
1 of 5
*
MIXED RESULTS FOR NOVARTIS’ ENTRESTO PRESENTED AT ESC*
LOOK BACK AT PHARMA NEWS IN THE WEEK TO AUGUST 30*
AUGUST 2019 PHARMACEUTICAL M&A ROUND-UP*
UK DOCTORS’ UNION WARNS OF ‘DEVASTATING’ IMPACT OF NO DEAL ONNHS
*
BIOSIMILAR HUMIRA CONTRIBUTES TO MASSIVE NHS COST SAVINGSCOMPANY
IMMATICS BIOTECHNOLOGIES A clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment ofcancer.
FDA BLOG
FDA ACTION ON MEDICATION LABELING INFORMATIONBOARDROOM
">
Article
BAYER APPOINTS NEW BUSINESS DEVELOPMENT HEAD FOR PHARMACEUTICALS03-09-2019
German pharma major Bayer has appointed Marianne De Backer as head of business development for pharmaceuticals. MERGERS & ACQUISITIONS AUGUST 2019 PHARMACEUTICAL M&A ROUND-UP Mega deals are rarely on the August agenda, and so it proved in 2019, with no companies being acquired by pharma's biggest players. Tweets by @ThePharmaLetterEVENTS
*
19TH ANNUAL BIOTECH IN EUROPE FORUM 25-09-2019 - 26-09-2019Basel An international platform for those interested in investing and partnering in the biotech and life sciences industry.*
8TH INTERAMERICAN ONCOLOGY CONFERENCE 17-10-2019 - 18-10-2019Buenos Aires, Argentina The 8th InterAmerican Oncology Conference will bring together oncology experts from North and South America to discuss the current status and future of anti-cancer therapies.*
ICH GLOBAL MEETING ON E8(R1) GENERAL CONSIDERATIONS FOR CLINICALTRIALS
31-10-2019 - 31-10-2019Washington DC The purpose of the meeting is to provide information and solicit input from a broad range of non-ICH member/observer stakeholders on the draft revised E8(R1) guideline General Considerations for ClinicalTrials.
*
11TH CONGRESS OF THE EUROPEAN PAIN FEDERATION 04-09-2019 - 07-09-2019Valencia, Spain This scientific congress on pain brings together experts in pain medicine to exchange knowledge, ideas and the latest advances in thefield.
*
BIOPHARM AMERICA 2019 11-09-2019 - 12-09-2019Boston, MA This event is part of Biotech Week Boston.*
19TH ANNUAL BIOTECH IN EUROPE FORUM 25-09-2019 - 26-09-2019Basel An international platform for those interested in investing and partnering in the biotech and life sciences industry.*
8TH INTERAMERICAN ONCOLOGY CONFERENCE 17-10-2019 - 18-10-2019Buenos Aires, Argentina The 8th InterAmerican Oncology Conference will bring together oncology experts from North and South America to discuss the current status and future of anti-cancer therapies.*
ICH GLOBAL MEETING ON E8(R1) GENERAL CONSIDERATIONS FOR CLINICALTRIALS
31-10-2019 - 31-10-2019Washington DC The purpose of the meeting is to provide information and solicit input from a broad range of non-ICH member/observer stakeholders on the draft revised E8(R1) guideline General Considerations for ClinicalTrials.
*
11TH CONGRESS OF THE EUROPEAN PAIN FEDERATION 04-09-2019 - 07-09-2019Valencia, Spain This scientific congress on pain brings together experts in pain medicine to exchange knowledge, ideas and the latest advances in thefield.
*
BIOPHARM AMERICA 2019 11-09-2019 - 12-09-2019Boston, MA This event is part of Biotech Week Boston.*
19TH ANNUAL BIOTECH IN EUROPE FORUM 25-09-2019 - 26-09-2019Basel An international platform for those interested in investing and partnering in the biotech and life sciences industry.1
2
3
4
5
PrevNext
SIGN UP FOR OUR DAILY NEWSLETTER Our latest news direct to your inboxNewsletter
* Login
* Subscribe
LINKS
* About us
* Subscribe
* Work for Us
* Contact us
* Terms and Conditions* Privacy Policy
* Drugs
* RSS
* PR Newswire Press ReleasesOUR MISSION
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
CONTACT US
The Pharma Letter
39 to 43 Putney High StreetPutney
London
SW15 1SP
For trial and subscription enquiries please email subscriptions@thepharmaletter.com For editorial enquiries, press releases and events please email newsdesk@thepharmaletter.com For all other queries please email enquiries@thepharmaletter.com Agile web development by Byte9Back to top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0